8-K: Cryoport Exceeds 2025 Revenue Guidance, Projects 8-10% Growth

Cryoport, Inc. announced strong financial results for Q4 and full-year 2025, surpassing revenue guidance and projecting continued growth for 2026.

Summary

• Full-year 2025 revenue increased to $176.2 million, exceeding the high end of previous guidance.
• Life Sciences Services revenue grew 18% year-over-year in FY 2025 to $96.5 million, including a 22% rise in BioStorage/BioServices revenue to $18.4 million.
• Commercial cell and gene therapy (CGT) revenue increased 29% year-over-year to $33.4 million in FY 2025.
• Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025.
• Full-year 2026 revenue guidance is set at $190 million to $194 million, representing 8%-10% growth year-over-year.
• Consolidated gross margin improved to 47.1% for FY 2025, up from 44.4% in FY 2024.
• Adjusted EBITDA from continuing operations improved by $12 million year-over-year to a negative $5.8 million for FY 2025.
• Net income for FY 2025 was $78.3 million, primarily driven by the divestiture of the CRYOPDP business.
• Held $411.2 million in cash, cash equivalents, and short-term investments as of December 31, 2025.
• Completed the divestiture of the CRYOPDP business to DHL Group on June 11, 2025, which included a substantial capital infusion and contributed $112.3 million net of taxes to income from discontinued operations.
• Launched a Global Supply Chain Center in Paris, France, and is targeting an opening for a fourth Global Supply Chain Center in Santa Ana, California in late 2026.
• MVE Biological Solutions introduced integrated Condition Monitoring Solutions for dry vapor shippers and launched the Fusion 800 Series, a self-sustaining cryogenic freezer.
• Cryoport Systems achieved certification under ISO 21973:2020 for transportation of cells for therapeutic use.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, highlighted by exceeding revenue guidance, significant growth in key segments like commercial CGT, and a substantial improvement in adjusted EBITDA, alongside a robust cash position from a strategic divestiture.

Positives

• FY 2025 revenue of $176.2 million exceeded the high end of previous guidance.
• Life Sciences Services revenue grew 18% year-over-year in FY 2025, demonstrating strong core business performance.
• BioStorage/BioServices revenue showed robust growth of 22% year-over-year in FY 2025.
• Commercial cell and gene therapy revenue increased significantly by 29% year-over-year to $33.4 million.
• Supported a record 760 global clinical trials and 20 commercially approved therapies, indicating strong market penetration and leadership.
• Consolidated gross margin improved to 47.1% for FY 2025 from 44.4% in FY 2024, reflecting enhanced operational discipline.
• Adjusted EBITDA from continuing operations improved by $12 million year-over-year to negative $5.8 million for FY 2025, showing progress towards profitability.
• Strong cash position with $411.2 million in cash, cash equivalents, and short-term investments as of December 31, 2025.
• Strategic divestiture of CRYOPDP to DHL Group provided a substantial capital infusion and contributed $112.3 million net of taxes to net income.
• Expanded global partnerships with Cardinal Health and Parexel, enhancing market reach and service integration.
• Introduction of innovative products by MVE Biological Solutions (Condition Monitoring Solutions, Fusion 800 Series) expands market opportunities.
• Cryoport Systems achieved ISO 21973:2020 certification, underscoring commitment to safety and traceability.

Negatives

• Adjusted EBITDA from continuing operations remains negative at $5.8 million for FY 2025, despite significant improvement.
• Net loss attributable to common stockholders for Q4 2025 was $13.6 million, or $0.27 per share.
• Life Sciences Products segment growth was 7% year-over-year, which is lower than the Life Sciences Services segment's growth.

Risks

• Effects of changing economic and geopolitical conditions.
• Supply chain constraints.
• Inflationary pressures.
• Tariffs and other trade restrictions.
• Foreign currency fluctuations.
• Trends in the products markets.
• Any U.S. federal government shutdown.
• Variations in the Company's cash flow.
• Market acceptance risks for new products and services.
• Technical development risks associated with new solutions.
• Risk that any disruption resulting from the DHL Transaction may adversely affect businesses and business relationships, including with employees and suppliers.

Future Outlook

Cryoport provides full-year 2026 revenue guidance in the range of $190.0 million to $194.0 million, representing 8%-10% year-over-year growth. The company anticipates 13 Biologics License Applications (BLA) / Marketing Authorization Applications (MAA) filings, nine new therapy approvals, and an additional two approvals for label/geographic expansions in 2026. Three clients are expecting new therapy approval decisions in March and April 2026. The Global Supply Chain Center in Santa Ana, California, is targeted for opening in late 2026, and IntegriCell's cryopreservation service centers are expected to contribute revenue throughout 2026.

Management Comments

• "2025 was a year of strong progress for Cryoport. We delivered full-year revenue of $176.2 million, exceeding the high end of our previous guidance and reflecting continued momentum across our core markets."
• "We achieved double-digit revenue growth driven by expanding cell and gene therapy (CGT) activity, with revenue from the support of commercial CGTs increasing 29% year-over-year to a record $33.4 million for FY 2025."
• "We believe our leadership position across both clinical and commercial programs, and the breadth of the development pipeline we support, provide a substantial foundation for sustained long-term growth."
• "While our primary focus remains on accelerating revenue growth and strengthening our market position, we continue to enhance operational discipline across the organization as we advance on our pathway to profitability."
• "As we enter 2026 and balance the global macro puts and takes, we believe that our full-year revenue guidance of $190 million to $194 million is an appropriate starting point for the year."

Industry Context

StockSavvy.ai notes that Cryoport's strong growth in Life Sciences Services, particularly in cell and gene therapy, aligns with the broader expansion of the regenerative medicine market. The strategic partnerships with DHL, Cardinal Health, and Parexel indicate a move towards deeper integration within the biopharmaceutical supply chain, a common trend for specialized logistics providers seeking to capture more value and expand global reach in a high-growth, high-compliance sector. The focus on operational discipline and pathway to profitability is crucial in a capital-intensive industry.

Comparison to Industry Standards

• Cryoport's support for 760 global clinical trials, representing approximately 70% of CGT trials, positions it as a dominant player in the specialized logistics for cell and gene therapies, significantly higher than smaller, regional competitors.
• The 29% year-over-year growth in commercial CGT revenue to $33.4 million demonstrates strong traction in a rapidly expanding, high-value segment, outperforming general pharmaceutical logistics growth rates which are typically in the mid-single digits.
• The improvement in adjusted EBITDA from -$17.8 million to -$5.8 million, while still negative, shows progress towards profitability, a key metric for specialized logistics companies that often require significant upfront investment in infrastructure and technology.

Stakeholder Impact

• Shareholders: Positive impact due to exceeding revenue guidance, improved profitability metrics, strong cash position, and an active share repurchase program. The CRYOPDP divestiture provided a significant capital infusion and contributed to net income.
• Customers: Enhanced service offerings through new Global Supply Chain Centers (Paris, Santa Ana), expanded integrated services (BioStorage/BioServices), new product introductions (MVE Fusion 800 Series, Condition Monitoring Solutions), and ISO 21973:2020 certification, all aimed at improving reliability and safety for temperature-sensitive materials.
• Employees: Potential for growth and expansion with new facilities and strategic partnerships, though 'cost reduction initiatives' were mentioned, which could imply some impact.
• Partners (DHL, Cardinal Health, Parexel): Strengthened relationships and expanded market reach through strategic collaborations.

Next Steps

• Opening of Global Supply Chain Center in Santa Ana, California in late 2026.
• Anticipated 13 BLA/MAA application filings in 2026.
• Anticipated nine new therapy approvals in 2026.
• Anticipated two label/geographic expansions in 2026.
• Three clients anticipating new therapy approval decisions in March and April 2026.
• Filing of Annual Report on Form 10-K for FY 2025 on March 6, 2026.
• Earnings conference call on March 3, 2026.

Key Dates

Recommendation

Cryoport delivered robust financial performance, exceeding revenue guidance for FY 2025, driven by strong double-digit growth in its core Life Sciences Services and commercial cell and gene therapy segments. The significant improvement in adjusted EBITDA, coupled with a substantial cash position from the strategic CRYOPDP divestiture, provides a solid financial foundation. The positive 2026 revenue guidance, continued expansion of clinical trial support, and strategic partnerships position the company for sustained long-term growth in the high-demand regenerative medicine market. The share repurchase program also indicates management's confidence.

Keywords

Cryoport, CYRX, financial results, Q4 2025, FY 2025, cell and gene therapy, CGT, life sciences, supply chain, temperature-controlled logistics, biopharma, biostorage, bioservices, MVE Biological Solutions, cryogenic systems, DHL, Cardinal Health, Parexel, clinical trials, commercial therapies, revenue guidance, adjusted EBITDA